1-(3-氯-2-三氟甲基-苯基)-哌嗪 | 1007455-86-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氯-2-三氟甲基-苯基)-哌嗪
• 英文名称: 1-(3-chloro-2-trifluoromethyl-phenyl)-piperazine
• 英文别名: 1-[3-Chloro-2-(trifluoromethyl)phenyl]piperazine
• CAS: 1007455-86-8
• 化学式: C₁₁H₁₂ClF₃N₂
• 分子量: 264.678
• InChiKey: QKDJQFQXOLXZIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yloxy)-butyraldehyde 、 1-(3-氯-2-三氟甲基-苯基)-哌嗪 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 7-(4-(4-(3-chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)butoxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

  摘要：

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.059
• 作为产物：
  描述：

  1-(3-氯-2-三氟甲基-苯基)-哌嗪盐酸盐 在 氢氧化钾 作用下， 以 水 、 甲苯 为溶剂， 生成 1-(3-氯-2-三氟甲基-苯基)-哌嗪
  参考文献：
  名称：

  7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE

  摘要：

  本发明涉及一种具有式(I)的化合物或其药用可接受的盐，包含该化合物或其盐的药物组合物，以及其作为治疗精神分裂症、双相情感障碍或其他中枢神经系统疾病的药物的用途。

  公开号：

  US20080167319A1

文献信息

• [EN] ISOINDOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOINDOLE
  申请人：PFIZER PROD INC

  公开号：WO2008020306A2

  公开（公告）日：2008-02-21

  [EN] This invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, a process of making these compounds, pharmaceutical compositions containing one or more of these compounds or their salts, and their use for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.
  [FR] La présente invention concerne des composés de formule (I) ou leurs sels pharmaceutiquement acceptables, un procédé de fabrication de ces composés, des compositions pharmaceutiques contenant un ou plusieurs de ces composés ou leurs sels et leur utilisation pour le traitement de la schizophrénie, du trouble bipolaire ou d'autres affections du système nerveux central.
• [EN] NAPHTHYRIDINONE COMPOUND<br/>[FR] COMPOSÉ DE NAPHTYRIDINONE
  申请人：PFIZER PROD INC

  公开号：WO2008084324A1

  公开（公告）日：2008-07-17

  [EN] This invention relates to a compound of formula (I) (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compound or a salt thereof, and its use as a medicament for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.
  [FR] Cette invention porte sur un composé de la formule (I), ou sur des sels pharmaceutiquement acceptables de celui-ci, sur des compositions pharmaceutiques comprenant le composé ou un sel de celui-ci, et sur son utilisation comme médicament pour le traitement de la schizophrénie, du trouble bipolaire ou d'autres troubles du système nerveux central.
• Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder
  作者：Douglas S. Johnson、Chung Choi、Lorraine K. Fay、David A. Favor、Joseph T. Repine、Andrew D. White、Hyacinth C. Akunne、Lawrence Fitzgerald、Kim Nicholls、Bradley J. Snyder、Steven Z. Whetzel、Liming Zhang、Kevin A. Serpa

  DOI：10.1016/j.bmcl.2011.01.059

  日期：2011.5

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.
• 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE
  申请人：Favor David Alan

  公开号：US20080167319A1

  公开（公告）日：2008-07-10

  This invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compound or a salt thereof, and its use as a medicament for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.

  本发明涉及一种具有式(I)的化合物或其药用可接受的盐，包含该化合物或其盐的药物组合物，以及其作为治疗精神分裂症、双相情感障碍或其他中枢神经系统疾病的药物的用途。